Telavant, a Roivant company, is developing innovative therapies to help patients living with inflammatory and fibrotic diseases.

Product Candidates
We are developing RVT-3101 as a potential best-in-class and first-in-class subcutaneous therapy in ulcerative colitis and Crohn’s disease, including for patients with a prospectively defined biomarker who may benefit from a precision approach utilizing RVT-3101.
Our Team
Filter by Role

Frank Torti, MD
Chairman and Chief Executive Officer

Bittoo Kanwar, MD
Chief Medical Officer

Joe Bishop
Chief Financial Officer

Amy Mahery
Chief Commercial Officer

Srini Ramanathan, PhD
Chief Development Officer

Navneet Alag
Governance

Ameer Basrai
CMC

Kathleen Boruchowski
Data Management

Jason Chamberlain, PhD
Nonclinical Development

Xiao-Dong Chen, PhD
CMC

Jean Dodge, PharmD
Pharmacovigilance

Craig Dyar, PhD
Quality

Eric Gaukel
Nonclinical Development

Hilary Hafeken
Regulatory

Anne Hansen
Data Management

Reed Johnson
Program Management

Li-Yin Lee, PhD
Biometrics

Min Lin, PhD
Biometrics

Shingai Majuru, PhD
CMC

Lee O’Brien, PhD
Regulatory

Marie Parrish, PhD
Regulatory

Dan Patterson, PhD
CMC

Sudhir Penugonda, MD
Clinical Development

Amber Silva
Clinical Operations

Victoria Silva, PhD
CMC

Brenton Smith, PhD
Program Management

Winston Su, PharmD
Regulatory

Suzanne Vyvoda
Clinical Operations

Eric Wasserstrum
Governance

Emily Weng, ScD
Biometrics

Yan Xin, PhD
Clinical Pharmacology

Jianhui (Jimmy) Zhao
Biometrics

Frank Torti, MD
Chairman and Chief Executive Officer

Irena Melnikova, PhD
Director
